The decision, which is for HNSCC, brings the UK “further out of step with clinical practice in the rest of the world.”
News
Could gut bacteria guard against Parkinson’s?
The results are the latest in a number of recent studies which have found a link between brain function and the digestive system.
Cyber attacks hit more than half of healthcare orgs in last year
Despite the vulnerability to cyber attacks, just 24% of companies have an adequate level of budget allocated to cyber security.
PTC submits MAA for new gene therapy
The company expects a CHMP decision in the second half of 2020.
Horizon enlists Mammoth in CRISPR move
The San Fransisco-based biotech built the first CRISPR-based detection platform for diagnostics.
Genomics England, Illumina join forces on whole genome sequencing
The partnership comes off the back of the success of the 100,000 Genomes Project in December 2018.
Novartis, NHS strike ‘innovative’ cardiovascular deal
Novartis’ inclisiran will be studied in UK patients as part of a large-scale NHS clinical trial, which is expected to start later this year.
Zytiga, Ajovy among latest SMC decisions
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Lynparza granted Priority Review in US
The first-in-class PARP inhibitor was also recently approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer.
Elasmogen secures £2m to support next gen biologics
The Scottish company currently has drug libraries of more than 100 billion unique soloMERs.
Eli Lilly set to acquire Dermira, including lebrikizumab
The deal is valued at around $1.1 billion.
ViiV submits fostemsavir MAA to EMA
The application is based on results from the BRIGHTE study, in which the drug showed superiority to placebo.
December NHS stats show wait times ‘worst on record’
The situation is being called “totally unacceptable”, with experts demanding “urgent action.”
New ‘fast-track’ system for tinnitus and hearing loss
Currently there are no registered pharmaceutical treatments for hearing loss or tinnitus.
Economic burden of cancer costs UK £7.6bn a year
A report has found that as many as 53% of people with cancer see their income fall by at least one income bracket.
